Arvest Bank Trust Division Invests $21.08 Million in IQVIA Holdings Inc. (NYSE:IQV)

Arvest Bank Trust Division acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 88,953 shares of the medical research company’s stock, valued at approximately $21,079,000. IQVIA comprises 1.2% of Arvest Bank Trust Division’s investment portfolio, making the stock its 26th biggest position.

Several other institutional investors have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP acquired a new position in IQVIA during the 3rd quarter valued at approximately $27,000. Park Place Capital Corp acquired a new position in shares of IQVIA during the third quarter valued at $28,000. Itau Unibanco Holding S.A. bought a new position in shares of IQVIA during the second quarter worth about $29,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth about $32,000. Finally, Avior Wealth Management LLC lifted its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. TD Cowen cut their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. BTIG Research decreased their price target on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Barclays cut their price objective on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Wednesday. Finally, Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $257.87.

IQVIA Stock Performance

IQVIA stock opened at $201.05 on Thursday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The firm’s 50 day simple moving average is $214.01 and its 200-day simple moving average is $224.77. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $36.49 billion, a P/E ratio of 26.38, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.